5 Insightful Analyst Questions From Medifast’s Q3 Earnings Call

Medifast’s third quarter results met Wall Street’s revenue expectations, but the market responded negatively as sales continued to decline sharply year-over-year. Management attributed these results to ongoing headwinds in the weight loss industry—most notably, increased competition from GLP-1 medications and declines in the number of active earning coaches. CEO Dan Chard highlighted that the company’s evolving science-backed approach to metabolic health aims to differentiate Medifast in a changing landsca ...